Loading clinical trials...
Loading clinical trials...
A Phase II Randomized Study to Assess the Efficacy on Outcome of Venetoclax Combined With Cytarabine Versus Idarubicin Combined With Cytarabine Administered as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission
Conditions
Interventions
Cytarabine-Venetoclax Association
Cytarabine-Idarubicin Association
Locations
26
France
ANGERS - CHU - Maladies du sang
Angers, France
ANNECY - Centre Hospitalier Annecy-Genevois
Annecy, France
AVIGNON - Centre Hospitalier
Avignon, France
BAYONNE - CH de la Côte Basque - Hématologie
Bayonne, France
BESANCON - Hôpital Jean Minjoz - Hématologie
Besançon, France
BEZIERS - Centre Hospitalier - Hématologie
Béziers, France
Start Date
May 25, 2022
Primary Completion Date
August 15, 2025
Completion Date
January 31, 2029
Last Updated
June 27, 2024
NCT06285890
NCT06220162
NCT04065399
NCT04628026
NCT06484062
NCT06994676
Lead Sponsor
French Innovative Leukemia Organisation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions